Evan David Seigerman
Stock Analyst at BMO Capital
(1.90)
# 2,848
Out of 4,818 analysts
36
Total ratings
21.88%
Success rate
-0.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $62.63 | +2.19% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $79.81 | +20.29% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $180.37 | +19.20% | 7 | Feb 3, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $9.08 | +197.36% | 3 | Jan 22, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,300 → $1,190 | $599.21 | +98.59% | 5 | Nov 1, 2024 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $23.66 | +322.65% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $279.84 | +26.86% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $22.78 | +58.03% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $5.00 | -40.00% | 1 | May 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $369 → $396 | $859.73 | -53.94% | 1 | Sep 6, 2022 |
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $62.63
Upside: +2.19%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $79.81
Upside: +20.29%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $180.37
Upside: +19.20%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $9.08
Upside: +197.36%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,300 → $1,190
Current: $599.21
Upside: +98.59%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $23.66
Upside: +322.65%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $279.84
Upside: +26.86%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $22.78
Upside: +58.03%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.00
Upside: -40.00%
Eli Lilly and Company
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $859.73
Upside: -53.94%